

Onconova Therapeutics

The path forward for rigosertib (IV)

Onconova recently updated the scientific and investment communities on its development plans for rigosertib (IV) in myelodysplastic syndrome (MDS). While another Phase III trial will be necessary to gain FDA approval, European Medicines Agency (EMA) draft guidelines regarding subgroup analyses of clinical studies suggest a filing in Europe with the existing data may be possible. We expect clarity on the Phase III protocol necessary for US approval and the EU regulatory path in Q115. We have adjusted our valuation slightly to \$254m or \$11.70 per share.

Year end	Revenue (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)	Yield (%)
12/13	4.8	(62.2)	(6.05)	0.0	N/A	N/A
12/14e	0.8	(65.2)	(2.99)	0.0	N/A	N/A
12/15e	4.0	(64.0)	(2.87)	0.0	N/A	N/A
12/16e	4.0	(66.1)	(2.90)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

Healthier data in sicker patients

While the ONTIME trial failed on an intent-to-treat (ITT) basis, subgroup analyses presented at the American Society of Hematology (ASH) illuminate the path forward for the programme. In a pre-defined subgroup of patients who progressed on or failed to respond to previous treatment with hypomethylating agents(HMAs), rigosertib demonstrated a 4.1-month survival benefit with a hazard ratio(HR) of 0.63 and a p-value of 0.01. The data also showed encouraging trends or statistically significant benefits in a number of cytogenetic abnormalities, and in patients deemed 'very high risk', according to a revised international prognostic scoring system (IPSS-R).

Early filing in Europe possible

Recent EMA draft guidelines on the use of subgroup analyses indicate that a filing in the EU, with the data already in hand, could be possible. This would trigger a \$50mmilestone from EU partner Baxter upon Baxter's decision to file with the EMA, and another \$25mupon the actual filing. This scenario would lead to meaningful upside for shares as the milestones equate to \$3.50 a share and would eliminate the need for a dilutive financing in 2015, the possibility of which is currently overhanging shares.

Valuation: Adjusted to \$254m, or \$11.60 per share

We have lowered our valuation slightly to \$254m, or \$11.70 per basic share, from \$262m, or \$12.1 per basic share, previously, due to a number of factors. Most notably we have lowered our rNPV for rigosertib IV. This is as a result of increased R&D expenses and lower profitability for the product post-launch, partially offset by increasing the chance of success from 50% to 60%, due to increased clarity on the data set. Our valuation suggests upside potential in the stock, which could start to be realised upon FDA and EMA clarity on the clinical and regulatory path for rigosertib (IV).

Regulatory/clinical update

Pharma & biotech

N/A

9 January 2015Price\$4.41Market cap\$96mNet cash (\$m)at end September 201457.3Shares in issue21.7Free float55.5%CodeONTXPrimary exchangeNASDAQ

Share price performance

Secondary exchange



Business description

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule drug candidates to treat cancer. Its lead drug candidate, rigosertib, is partnered with Baxter (Europe) and SymBio (Japan/Korea).

Next events

Decision on US pivotal trial design	n Q115
Clarity on EMA path to approval	Q115
Start oral rigosertib Phase III stud lower-risk MDS	y in H215
Analysts	
Maxim Jacobs CFA	+1 646 653 7027

Maxim Jacobs, CFA	+1 646 653 7027
Dr Mick Cooper	+44 (0)20 3077 5734

healthcare@edisongroup.com

Edison profile page



The path forward for rigosertib (IV) in higher risk MDS

At ASH, as well as at an analyst and investor event in New York, Onconova presented the potential path forward for rigosertib IV thanks to very compelling data in predefined or cytogenetic subgroups, which generally represented the sickest patients. The largest subgroup were primary HMA failures (those who had no response to HMA therapy, representing 64% of the trial population) where there was a significant benefit for patients in the treatment arm versus those receiving best supportive care. There was a 4.1-month median survival benefit (Exhibit 1), with an HR of 0.63 (p=0.011).




Exhibit 1: Kaplan-Meier Curve in the primary HMA failure subgroup in the ONTIME trial

There was also a benefit observed across several cytogenetic abnormalities (Exhibit 2), with significant benefits in Monosomy 7 patients (~10% of the total) and Trisomy 8 patients (~10% of the total) and a strong trend in Del 7q patients (~7% of the total).There was also a significant benefit among those labelled 'very high risk' according to IPSS-R (~45% of the total).

Exhibit 2: Cytogenetic and IPSS-R subgroup of	data in the ONTIME trial

	Rigosertib			BSC				
Subgroup	N	Median (mos)	N	Median (mos)	HR (95% CI)	p-value		
Monosomy 7	16	5.6	13	2.8	0.24	0.003		
					(0.09-0.66)			
Trisomy 8	22	9.5	8	4.5	0.34	0.035		
					(0.12-0.95)			
Del 7q	17	5.0	3	2.7	0.38	0.14		
					(0.10-1.48)			
Very high risk	93	7.6	41	3.2	0.56	0.005		
per IPSS-R					(0.37-0.84)			

Source: Onconova Therapeutics; ASH 2014

In order to gain FDA approval for rigosertib IV, Onconova plans to amend the protocol in its ongoing 04-24 study, a single-arm trial in HMA failures, and potentially use it for registration purposes. The company has said that the FDA is open to the use of a single-arm trial for this purpose, which would be easier to enrol as patients would not have to risk receiving no active therapy (while no therapy is

Source: Onconova Therapeutics; ASH 2014



approved for HMA failures, patients may opt to go on other clinical trials) and would probably only require100-150 patients (~50 patients are already enrolled in the trial). The endpoint could be based on IWG response criteria and not survival. Under this scenario, the timing of the confirmatory trial would be much quicker than currently expected and the associated expenses lower. We should receive clarity on the US registration trial design in Q115.

Potential filing in Europe

In Europe, there is a chance that Onconova and its EU partner Baxter could file for approval based on the data they already have. Earlier in 2014, the EMA published draft guidelines titled "Guidelines on the investigation of subgroups in confirmatory clinical trials" where it indicates that approval based on subgroup analysis from one trial is possible. The company mentioned eight key criteria from these guidelines (summarised below):

- 1. Life-threatening condition and high unmet medical need.
- Data from at least one additional trial to replicate the subgroup effect. Data from other trials may be relevant. In the case of a single pivotal study, the biological plausibility and clinical trial data would have to be exceptionally strong.
- 3. Clear rationale why the trial failed despite the drug being efficacious.
- 4. A well-defined and clinically relevant subgroup.
- 5. Pharmacological or mechanistic explanation why there is a different efficacy in a subgroup versus the rest of the population.
- 6. A larger treatment effect in the subgroup in absolute terms versus the intent-to-treat population.
- 7. Strong statistical evidence that the treatment effect is not random.
- 8. Careful assessment of the overall evidence and demonstration of credibility.

The company seems to meet at least seven of the eight criteria, with the big unknown being number two. The company has not disclosed whether it saw efficacy in the same subgroups in the earlier Phase I and Phase II studies as it did in the ONTIME trial, but if it did, that would buttress its argument for filing with the EMA early, with a confirmatory trial coming post-approval. If it were to file early, it would receive \$50mfrom EU partner Baxter upon the decision to file, and an additional \$25mupon the filing itself, amounting to \$3.50/share in cash. That said, this scenario would depend on the outcome of ongoing discussions with the EMA as well as the agreement of Baxter, neither of which can be predicted with any certainty at this time.

If an early filing is not possible, the company would seek to repurpose the 04-24 study to meet registration requirements in the EU. However, while the FDA is amenable to using response criteria, the EMA would want an overall survival endpoint, which means that it would take longer to get a readout for the EMA than for the FDA. Our base scenario continues to be a launch in the US and EU in 2017 for rigosertib IV.

Optimising the oral programme in lower-risk MDS

In our view, the oral programme in lower-risk MDS patients represents the bulk of the value and ultimate potential of Onconova as it would be targeting a larger market (frontline patients) and, assuming IV is approved, be extremely profitable for the company (as it would be sold through an existing sales and marketing infrastructure). Timing of the initiation of the pivotal clinical trial is to be determined and will depend upon funding, results and approvals. The company still needs to optimise the dose and is still developing a prognostic genomic test, which would help it enrich the patient pool of the trial to its benefit (making sure those patients with mutations that have historically responded to rigosertib are enrolled in the trial).



Front-line potential in MDS/AML through combination use

Onconova is testing the use of oral rigosertib as a front-line therapy in MDS/AML patients in combination with azacitidine. Preclinical data showed a distinct synergistic effect when rigosertib is used in combination with azacitidine in leukemic cells (See Exhibit 3).

Exhibit 3: Synergy data of rigosertib+azacitidine

Combin	Combination index (CI) values from median-effect analysis [†]									
Drug C	_									
Rigosertib Azacitidine (nM) (nM)		Ratio	C.I.‡	Comment						
125	2000	1:63	0.44	synergism						
125	4000	1:31	0.30	strong synergism						
250	2000	1:125	0.68	synergism						
250	4000	1:63	0.57	synergism						
500	2000	1:250	0.63	synergism						
500	4000	1:125	0.75	moderate synergism						

[†]HL-60 cells (1 x 10⁶/mL) were first exposed to (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl) methyl)-2-methoxyphenylamino)acetic acid sodium salt ("Compound A") (125, 250, or 500 nM). After 24 h, azacitidine (2000 or 4000 μ M) was added. The cytotoxic effect of the drug combination was evaluated at 72 h. ⁴C.I. < 1 indicates synergism.

Source: Onconova Therapeutics; US Patent 8,664,272

We saw some hints of that in the data from a Phase I trial of oral rigosertib and azacitidine, which was also presented at ASH. Out of 18 patients, five had marrow complete remissions and an additional four had a complete remission with incomplete recovery of blood counts. Importantly, the addition of oral rigosertib to azacitidine did not worsen the adverse event profile compared to that of azacitidine alone. If this and the efficacy hold up, this would make the addition of oral rigosertib to front-line azacitidine therapy much more compelling from a medical point of view. The Phase II portion of this combination trial is currently open in the US and EU and we look forward to seeing additional data from this exciting programme. We continue to expect approval for rigosertib oral as a single agent in the US and EU in 2018.

Valuation

We have updated our valuation of Onconova after the Q314 results as well as the recent data presentations. We have lowered our rNPV for rigosertib IV in second-line, higher-risk MDS to \$69m from \$101m previously. This is as a result of increased R&D expenses and lower profitability for the product post-launch, partially offset by increasing the chance of success from 50% to 60%, as there seems to be compelling data that the drug is efficacious in various defined subsets of patients. We have also increased our rNPV for rigosertib oral in lower-risk MDS to \$122m from \$113m previously to reflect greater profitability post-launch, due to the advantages of using an already existing sales and marketing infrastructure. This approach yields an intrinsic value of \$209m for the pipeline. Adding forecast year-end 2014 cash of \$45.3 yields a total value of \$254m, equivalent to \$11.70 per basic share (\$11.60 per diluted share, after options). Previously, we had valued Onconova at \$262m, or \$12.10 per basic share (\$11.50 per diluted share).



Product	Main Indication	Status	Prob. of success	Launch year	Peak sales (\$m)	Patent protection	Royalty	rNPV (\$m)
Rigosertib (IV)	2nd-line MDS, higher risk	Phase III	60%	2017	366	2026	Fully own in US; low teens	69
Rigosertib (oral)	MDS, lower- risk, non-5q-	Phase II	35%	2018	942	2026	to high 20s for EU	122
ON 013105	Head & neck	Phase I	25%	2019	149	>2026	Fully own	9
Recilisib	Acute radiation syndrome	Phase I		N/A			To be licensed out	10
Total								209
Cash and cash ec	uivalents (YE14e)	(\$m)						44.9
Total firm value (\$	m)							254.0
Total basic shares	(m)							21.8
Value per basic sh	are (\$)							11.6
Stock options (3/2	014, m)							4.1
Weighted average	exercise price (\$)							11.1
Cash on exercise	(\$m)							45.8
Total firm value (\$	m)							299
Total number of sh	nares							25.9
Diluted value per	share (\$)							11.6

Financials

Onconova reported a net loss of \$14.8m for Q314, including G&A expenses of \$3.1m and R&D costs of \$11.9m. The company ended the quarter with cash and cash equivalents of \$57.3m. We have changed our 2014 forecast slightly based on actual Q314 results and we now estimate Onconova will end the year with cash of \$45m. We estimate that Onconova would need additional financing of c \$47m in 2015 to support its operation if the current burn rate continues and no milestone payment is to be received from its partners.



Exhibit 5: Financial summary

	\$m	2011	2012	2013	2014e	2015e	2016e
Year end 31 December		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS							
Revenue		1.5	46.2	4.8	0.8	4.0	4.0
Cost of Sales		0.0	0.0	0.0	0.0	0.0	0.0
Gross Profit		1.5	46.2	4.8	0.8	4.0	4.0
EBITDA		(27.9)	(44.7)	(70.7)	(71.9)	(66.5)	(68.6)
Operating Profit (before amort. and except.)		(27.6)	(22.3)	(62.2)	(65.2)	(64.0)	(66.1)
Intangible Amortisation		0.0	0.0	0.0	0.0	0.0	0.0
Exceptionals		1.3	0.4	0.0	0.0	0.0	0.0
Other		0.0	0.6	0.1	0.0	0.0	0.0
Operating Profit		(26.3)	(21.3)	(62.1)	(65.2)	(64.0)	(66.1)
Net Interest		(0.0)	(8.6)	(0.0)	(0.0)	(0.0)	(0.0)
Profit Before Tax (norm)		(27.6)	(30.3)	(62.2)	(65.2)	(64.0)	(66.1)
Profit Before Tax (FRS 3)		(26.3)	(29.9)	(62.1)	(65.2)	(64.0)	(66.1)
Tax		0.0	0.0	0.4	0.0	0.0	0.0
Profit After Tax (norm)		(27.6)	(30.3)	(61.7)	(65.2)	(64.0)	(66.1)
Profit After Tax (FRS 3)		(26.3)	(29.9)	(61.7)	(65.2)	(64.0)	(66.1)
Average Number of Shares Outstanding (m)		2.14	2.21	10.59	21.80	22.30	22.80
EPS - normalised (\$)		(14.79)	(15.51)	(6.05)	(2.99)	(2.87)	(2.90)
EPS - normalised and fully diluted (\$)		(14.79)	(15.51)	(6.05)	(2.99)	(2.87)	
2 V 7		(14.79) (12.30)	(13.55)	(5.82)	(2.99)	(2.87)	(2.90)
EPS - (IFRS) (\$)		0.0	0.0	(5.62)	0.0	0.0	(2.90)
Dividend per share (\$)		0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET							
Fixed Assets		0.6	0.6	0.8	0.6	0.9	1.2
Intangible Assets		0.0	0.0	0.0	0.0	0.0	0.0
Tangible Assets		0.6	0.6	0.8	0.6	0.9	1.2
Investments		0.0	0.0	0.0	0.0	0.0	0.0
Current Assets		3.8	83.3	104.4	44.9	26.4	18.9
Inventory		0.0	0.0	0.0	0.0	0.0	0.0
Accounts receivable, net		0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalents		2.7	81.5	100.0	44.9	26.4	18.9
Other		1.1	1.7	4.4	0.0	0.0	0.0
Current Liabilities		(12.1)	(25.4)	(10.3)	(12.6)	(12.4)	(12.2)
Creditors		(5.6)	(5.5)	(3.7)	(5.8)	(5.3)	(4.8)
Short term borrowings		0.0	0.0	0.0	0.0	0.0	0.0
Accrued expenses/other		(6.5)	(19.9)	(6.6)	(6.8)	(7.1)	(7.4)
Long Term Liabilities		(10.8)	(15.5)	(13.9)	(13.1)	(56.1)	(112.1)
Deferred revenue, long term		(10.7)	(15.4)	(13.9)	(13.1)	(9.1)	(5.1)
Long-term borrowings		(0.1)	(0.0)	(0.0)	(0.0)	(47.0)	(107.0)
NetAssets		(18.4)	43.0	80.9	19.9	(41.1)	(104.3)
CASH FLOW		, ,					
Operating Cash Flow		(14.2)	1.6	(61.4)	(55.3)	(65.7)	(67.8)
Net Interest		(0.0)	0.0	(01.4)	(0.0)	(0.0)	(07.0)
Tax		0.0	0.0	0.0	0.0	0.0	0.0
Capex		(0.2)	(0.3)	(0.6)	(0.2)	(0.3)	(0.3)
•		0.0	0.0	0.0	0.0	0.0	0.0
Acquisitions/disposals							
Financing		9.8	77.5	79.8	0.5	0.5	0.5
Net Cash Flow		(4.6)	78.8	17.8	(55.1)	(65.5)	(67.6
Opening net debt/(cash)		(7.3)	(2.7)	(81.5)	(100.0)	(44.9)	20.6
HP finance leases initiated		0.0	0.0	0.0	0.0	0.0	0.0
Other		0.0	0.0	0.7	0.0	0.0	0.0
Closing net debt/(cash)		(2.7)	(81.5)	(100.0)	(44.9)	20.6	88.1

Source: Onconova Therapeutics accounts, Edison Investment Research. Note: The long-term borrowings of \$47m in FY15 are indicative of the company's funding requirement during this year.



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicOetalis.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Zi service Providers Registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Intel (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is regulated by the Australian Securities and Investment Commission. Edison Investment Research Limited (794244]. www.edisongrup.com

regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com DISCLAIMER Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Onconova Therapeutics and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to finexes and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation for inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an effer or solicitation for investment to any or related securities mentioned in this report. Edison or its affiliates may perform

disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (STSE 2015. "FTSE SEG)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany London+44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom New York+1 646 653 7026 245 Park Avenue, 39th Floor 10167, New York US Sydney+61 (0)2 9258 1161 Level 25, Aurora Place 88 Phillip St, Sydney NSW 2000, Australia

Wellington+64 (0)48 948 555 Level 15, 171 Featherston St Wellington 6011 New Zealand